Boston Scientific Corporation (BSX) Q4 2025 (USD): adj. EPS 0.80 (exp. 0.78), Revenue 5.29bln (exp. 5.28bln)

Boston Scientific's Q4 earnings slightly beat expectations on both adjusted EPS and revenue, which could lend positive momentum to their stock.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

Kraken says it is investigating an issue impacting spot, futures and API trading

Emirates considers orders for Airbus' (AIR FP) A350-2000 models

Boston Scientific Corporation (BSX) Q4 2025 (USD): adj. EPS 0.80 (exp. 0.78), Revenue 5.29bln (exp. 5.28bln)

Italy, France and Germany are reportedly set to lead EU critical materials stockpiling plan

German New Car Registrations YoY (Jan) Y/Y -6.6% (Prev. 9.7%)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.

GUIDANCE:

  • Q1 Rev. growth view +10.5-12.0% (exp. 5.21bln)
  • FY EPS view 3.43-3.49 (exp. 3.47)
Context

Their strong guidance for Q1 revenue growth and full-year EPS suggests continued confidence in their growth trajectory, potentially signaling strength in the healthcare equipment sector and influencing broader market sentiment.

Related headlines

The whole workspace, free to try.

Try it free